This draft guidance, once finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Oxybutynin chloride

Dosage Form/Route: Tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in vivo
   Strength: 5 mg at a dose of 10 mg (2x5 mg)
   Subjects: Healthy males and nonpregnant females, general population
   Additional comments: Not applicable (N/A)

2. Type of study: Fed
   Design: Single-dose, two-way crossover in vivo
   Strength: 5 mg at a dose of 10 mg (2x5 mg)
   Subjects: Healthy males and nonpregnant females, general population
   Additional comments: N/A

Analytes to measure (in appropriate biological fluid): Oxybutynin and its active metabolite N-desethyloxybutynin in plasma

Applicants should submit oxybutynin’s active metabolite data (N-desethyloxybutynin) as evidence further supportive of therapeutic equivalence. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and Cmax.

Bioequivalence based on (90% CI): Oxybutynin

Waiver request of in vivo testing: N/A

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).